Exceptional revenue growth near 63% per year and three consecutive earnings beats demonstrate strong commercial momentum, but deeply negative free cash flow consuming roughly 89% of revenues, below-floor business quality, and a technical setup that has not yet confirmed a resumption of trend strength combine to limit the investable case despite the growth trajectory.
Thesis pillars
- Exceptional Revenue Growth Rate→Stable
- Improving Earnings Beat Cadence↓Deteriorating
- Severe Cash Burn Viability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $21.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: ASSURE WCD; Negative momentum.
Kestra Medical Technologies is a commercial-stage medical device company selling the ASSURE wearable cardioverter defibrillator (WCD) as part of its Cardiac Recovery System platform, which protects patients at elevated risk of sudden cardiac arrest in a market historically... Read more
Hold if already holding. Not a fresh buy at $21.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: ASSURE WCD; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.7/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Kestra Medical Technologies, Lt
About Kestra Medical Technologies, Lt
Kestra Medical Technologies generated $59.8 million in revenue for the fiscal year ended April 30, 2025, up 115% from $27.8 million a year earlier, entirely from its ASSURE wearable cardioverter defibrillator, which received FDA premarket approval on July 27, 2021 and fully launched commercially in August 2022. The device has been worn by more than 20,000 patients, in a U.S.-focused market that, for over 20 years prior to ASSURE's approval, was served by a single competitor.
Kestra generates revenue almost entirely by leasing the ASSURE WCD to patients on a month-to-month basis, billing Medicare, Medicaid and private payors directly, with over 285 million U.S. lives covered by insurance contracts as of April 30, 2025, representing approximately 90% of total available lives. The company built a commercial infrastructure of approximately 80 direct sales representatives, more than 40 sales and clinical support professionals, and a contracted network of over 300 patient specialists who handle device fitting and training as of April 30, 2025. Devices are reprocessed and reintroduced into the distribution network after each patient's wear period, a fleet-based model built in collaboration with top-tier medical technology suppliers. Kestra holds more than 365 pending and issued patents worldwide as of April 30, 2025, and competes against a single incumbent WCD maker that has held the market for more than two decades.
Show full overview
Kestra's revenue depends almost entirely on a single product: the 10-K states that revenue from the ASSURE WCD and its associated Cardiac Recovery System services will continue to account for nearly all of the company's revenue for the foreseeable future, with no meaningfully diversified product line to offset a setback. That single-product dependency is compounded by a manufacturing base that relies on external suppliers for components, where the filing warns that an inability to secure timely supplies or qualify second-source suppliers if a primary supplier fails to deliver could impede the company's ability to manufacture and distribute its devices.
See also: Healthcare · Medical Instruments & Supplies
From Kestra Medical Technologies, Lt's most recent 10-K filing, extracted July 19, 2026.
Recent developments
updated 2026-07-26Recent Developments — Kestra Medical Technologies, Lt
Latest news
- NEWS Oppenheimer Initiates Coverage On Kestra Medical Techs with Perform Rating — benzinga Jul 21, 2026 positive
- NEWS BTIG Maintains Buy on Kestra Medical Techs, Raises Price Target to $32 — benzinga Jul 15, 2026 positive
- NEWS Kestra Medical Technologies Signs Five-Year, $200M Term Loan Financing — benzinga Jul 14, 2026 positive
- NEWS Kestra Medical Techs Sees FY2027 Sales $137.000M vs $132.895M Est — benzinga Jul 14, 2026 positive
- NEWS Kestra Medical Techs Q4 EPS $(0.67) Misses $(0.59) Estimate, Sales $28.638M Beat $26.479M Estimate — benzinga Jul 14, 2026 negative
Generated 2026-07-26T08:02:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductASSURE WCD10-K Item 1A: 'We generate revenue primarily from the lease of our ASSURE WCD as part of our Cardiac Recovery System platform, and we are therefore highly dependent on our ASSURE WCD for our continued success.'
- MEDIUMSupplierprimary suppliers10-K Item 1A: 'secure second source suppliers if our primary suppliers are unable to fulfill our orders'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $21.06, but acceptable to hold if already in. Reasons: Concentration risk — Product: ASSURE WCD; Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $26.10 (+23.9%), stop $19.79 (−6.4%), A.R:R 1.6:1. Score 5.7/10, moderate confidence.
Take-profit target: $26.10 (+23.9% upside). Target $26.10 (+23.9%), stop $19.79 (−6.4%), A.R:R 1.6:1. Stop-loss: $19.79.
Concentration risk — Product: ASSURE WCD; Negative momentum; Value-trap signals (2/5): Margin compression (op margin -137.4%), Negative free cash flow.
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -10.4). TrendMatrix value score: 5.1/10. Verdict: Hold.
13 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $30.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies is a commercial-stage medical device company selling the ASSURE wearable cardioverter...
Kestra Medical Technologies is a commercial-stage medical device company selling the ASSURE wearable cardioverter defibrillator (WCD) as part of its Cardiac Recovery System platform, which protects patients at elevated risk of sudden cardiac arrest in a market historically served by a single competitor for over 20 years. The company generated $59.8 million in revenue for the fiscal year ended April 30, 2025, up 115% from $27.8 million a year earlier, while recording a net loss of $113.8 million and an accumulated deficit of $520.2 million.